Extracellular visfatin activates gluconeogenesis in HepG2 cells through the classical PKA/CREB-dependent pathway

Hormone and Metabolic Research

Volumn 46, Issue 4, 2014, Pages 233-239

  Choi, Y J ^a   Choi, S E ^a   Ha, E S ^a   Kang, Y ^a   Han, S J ^a   Kim, D J ^a   Lee, K W ^a   Kim, H J ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

gluconeogenesis; insulin resistance; visfatin

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCOSE 6 PHOSPHATASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIRTUIN 1; MESSENGER RNA; SIRT1 PROTEIN, HUMAN;

ARTICLE; CELL STRAIN HEPG2; GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; DRUG EFFECTS; EXTRACELLULAR SPACE; GENETICS; HEPG2 CELL LINE; METABOLISM; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; EXTRACELLULAR SPACE; GLUCONEOGENESIS; HEP G2 CELLS; HUMANS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIRTUIN 1;

EID: 84899476892     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1370907     Document Type: Article

References (25)

1. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol: 1994; 14 1431 1437
2. Revollo J. R., Körner A., Mills K. F., Satoh A., Wang T., Garten A., Dasgupta B., Sasaki Y., Wolberger C., Townsend R. R., Milbrandt J., Kiess W., Imai S. Nampt/PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab: 2007; 6 363 375 (Pubitemid 350011996)
3. Dahl T. B., Holm S., Aukrust P., Halvorsen B. Visfatin/NAMPT: A Multifaceted Molecule with Diverse Roles in Physiology and Pathophysiology. Annu Rev Nutr: 2012; 32 229 243
4. Rasouli N., Kern P. A. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab: 2008; 93 01 S64 S73
5. Aller R., de Luis D. A., Izaola O., Sagrado M. G., Conde R., Velasco M. C., Alvarez T., Pacheco D., González J. M. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci: 2009; 54 1772 1777
6. Garten A., Petzold S., Barnikol-Oettler A., Körner A., Thasler W. E., Kratzsch J., Kiess W., Gebhardt R. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun: 2010; 391 376 381
7. Lee W. J., Wu C. S., Lin H., Lee I. T., Wu C. M., Tseng J. J., Chou M. M., Sheu W. H. Visfatin-induced expression of inï¬ammatory mediators in human endothelial cells through the NF-kappaB pathway. Int J Obes (Lond): 2009; 33 465 472
8. Dahl T. B., Yndestad A., Skjelland M., Oie E., Dahl A., Michelsen A., Damås J. K., Tunheim S. H., Ueland T., Smith C., Bendz B., Tonstad S., Gullestad L., Froland S. S., Krohg-Sorensen K., Russell D., Aukrust P., Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inï¬ammation and plaque destabilization. Circulation: 2007; 115 972 980 (Pubitemid 46328290)
9. Laudes M., Oberhauser F., Schulte D. M., Freude S., Bilkovski R., Mauer J., Rappl G., Abken H., Hahn M., Schulz O., Krone W. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res: 2010; 42 268 273
10. Zhong M., Tan H. W., Gong H. P., Wang S. F., Zhang Y., Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf): 2008; 69 878 884
11. Retnakaran R., Youn B. S., Liu Y., Hanley A. J., Lee N. S., Park J. W., Song E. S., Vu V., Kim W., Tungtrongchitr R., Havel P. J., Swarbrick M. M., Shaw C., Sweeney G. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf.): 2008; 69 885 893
12. Rabe K., Lehrke M., Parhofer K. G., Broedl U. C. Adipokines and insulin resistance. Mol Med: 2008; 14 741 751
13. Zhou H., Song X., Briggs M., Violand B., Salsgiver W., Gulve E. A., Luo Y. Adiponectin represses gluconeogenesis independent of insulin in hepatocytes. Biochem Biophys Res Commun: 2005; 338 793 799 (Pubitemid 41597713)
14. Miller R. A., Chu Q., Le Lay J., Scherer P. E., Ahima R. S., Kaestner K. H., Foretz M., Viollet B., Birnbaum M. J. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J Clin Invest: 2011; 121 2518 2528
15. Anderwald C., Müller G., Koca G., Fürnsinn C., Waldhäusl W., Roden M. Short-term leptin-dependent inhibition of hepatic gluconeogenesis is mediated by insulin receptor substrate-2. Mol Endocrinol: 2002; 16 1612 1628 (Pubitemid 34743678)
16. Chang Y. H., Chang D. M., Lin K. C., Shin S. J., Lee Y. J. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev: 2011; 27 515 527
17. Rodgers J. T., Lerin C., Haas W., Gygi S. P., Spiegelman B. M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature: 2005; 434 113 118 (Pubitemid 40349395)
18. Zhang T., Berrocal J. G., Frizzell K. M., Gamble M. J., DuMond M. E., Krishnakumar R., Yang T., Sauve A. A., Kraus W. L. Enzymes in the NAD+salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem: 2009; 284 20408 20417
19. Herzig S., Long F., Jhala U. S., Hedrick S., Quinn R., Bauer A., Rudolph D., Schutz G., Yoon C., Puigserver P., Spiegelman B., Montminy M. CREB regulates hepatic gluconeogenesis via the co-activator PGC-1. Nature: 2001; 413 179 183 (Pubitemid 32867880)
20. Ozcan L., Wong C. C., Li G., Xu T., Pajvani U., Park S. K., Wronska A., Chen B. X., Marks A. R., Fukamizu A., Backs J., Singer H. A., Yates J. R. 3rd, Accili D., Tabas I. Calcium Signaling through CaMKII Regulates Hepatic Glucose Production in Fasting and Obesity. Cell Metab: 2012; 15 739 751
21. Cao W., Collins Q. F., Becker T. C., Robidoux J., Lupo E. G. Jr, Xiong Y., Daniel K. W., Floering L., Collins S. p38 Mitogen-activated protein kinase plays a stimulatory role in hepatic gluconeogenesis. J Biol Chem: 2005; 280 42731 42737 (Pubitemid 43049233)
22. Asada S., Daitoku H., Matsuzaki H., Saito T., Sudo T., Mukai H., Iwashita S., Kako K., Kishi T., Kasuya Y., Fukamizu A. Mitogen-activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1. Cell Signal: 2007; 19 519 527 (Pubitemid 46107803)
23. Mlinar B., Marc J., Janez A., Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta: 2007; 375 20 35 (Pubitemid 44584240)
24. Esteghamati A., Alamdari A., Zandieh A., Elahi S., Khalilzadeh O., Nakhjavani M., Meysamie A. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract: 2011; 91 154 158
25. Jiang G., Zhang B. B. Glucagon and regulation of 3 glucose metabolism. Am J Physiol Endocrinol Metab: 2003; 284 E671 E678